Literature DB >> 22215557

Quantification of mtDNA mutation heteroplasmy (ARMS qPCR).

Victor Venegas1, Michelle C Halberg.   

Abstract

Pathogenic mitochondrial DNA (mtDNA) mutations are usually present in heteroplasmic forms that vary in concentration among different tissues. Manifestation of clinical phenotypes depends on the degree of mtDNA mutation heteroplasmy (mutation load) in affected tissues. It is therefore important to quantify the degree of mutation heteroplasmy in various tissues. In this chapter, we outline the design of allele refractory mutation system (ARMS)-based quantitative PCR (qPCR) analysis of common mtDNA point mutations, a cost-effective and sensitive single-step method to simultaneously detect and quantify heteroplasmic mtDNA point mutations.

Mesh:

Substances:

Year:  2012        PMID: 22215557     DOI: 10.1007/978-1-61779-504-6_21

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  10 in total

Review 1.  Challenges of bringing next generation sequencing technologies to clinical molecular diagnostic laboratories.

Authors:  Lee-Jun C Wong
Journal:  Neurotherapeutics       Date:  2013-04       Impact factor: 7.620

2.  Real-Time PCR Quantification of Heteroplasmy in a Mouse Model with Mitochondrial DNA of C57BL/6 and NZB/BINJ Strains.

Authors:  Thiago Simões Machado; Carolina Habermann Macabelli; Juliano Rodrigues Sangalli; Thiago Bittencourt Rodrigues; Lawrence Charles Smith; Flávio Vieira Meirelles; Marcos Roberto Chiaratti
Journal:  PLoS One       Date:  2015-08-14       Impact factor: 3.240

3.  Heteroplasmy of mutant mitochondrial DNA A10398G and analysis of its prognostic value in non-small cell lung cancer.

Authors:  Yuexiao Qi; Yuehua Wei; Qiaoli Wang; Hui Xu; You Wang; Anqi Yao; Hui Yang; Yan Gao; Fuxiang Zhou
Journal:  Oncol Lett       Date:  2016-09-05       Impact factor: 2.967

4.  TALEN-mediated shift of mitochondrial DNA heteroplasmy in MELAS-iPSCs with m.13513G>A mutation.

Authors:  Naoki Yahata; Yuji Matsumoto; Minoru Omi; Naoki Yamamoto; Ryuji Hata
Journal:  Sci Rep       Date:  2017-11-14       Impact factor: 4.379

5.  Benchmarking the Effectiveness and Accuracy of Multiple Mitochondrial DNA Variant Callers: Practical Implications for Clinical Application.

Authors:  Eddie K K Ip; Michael Troup; Colin Xu; David S Winlaw; Sally L Dunwoodie; Eleni Giannoulatou
Journal:  Front Genet       Date:  2022-03-08       Impact factor: 4.599

6.  Exposure to a Pathological Condition May Be Required for the Cells to Secrete Exosomes Containing mtDNA Aberration.

Authors:  Manjusha Vaidya; Sandeep Sreerama; Mariana Gaviria; Kiminobu Sugaya
Journal:  J Nucleic Acids       Date:  2022-03-17

7.  Interference of Co-amplified nuclear mitochondrial DNA sequences on the determination of human mtDNA heteroplasmy by Using the SURVEYOR nuclease and the WAVE HS system.

Authors:  Hsiu-Chuan Yen; Shiue-Li Li; Wei-Chien Hsu; Petrus Tang
Journal:  PLoS One       Date:  2014-03-24       Impact factor: 3.240

8.  Patient-derived lymphoblastoid cell lines harboring mitochondrial DNA mutations as tool for small molecule drug discovery.

Authors:  Randall Marcelo Chin; Tadas Panavas; Jeffrey M Brown; Krista K Johnson
Journal:  BMC Res Notes       Date:  2018-03-27

9.  Validation of a mitochondrial RNA therapeutic strategy using fibroblasts from a Leigh syndrome patient with a mutation in the mitochondrial ND3 gene.

Authors:  Yuma Yamada; Kana Somiya; Akihiko Miyauchi; Hitoshi Osaka; Hideyoshi Harashima
Journal:  Sci Rep       Date:  2020-05-05       Impact factor: 4.379

10.  MYC regulates fatty acid metabolism through a multigenic program in claudin-low triple negative breast cancer.

Authors:  Jessica C Casciano; Caroline Perry; Adam J Cohen-Nowak; Katelyn D Miller; Johan Vande Voorde; Qifeng Zhang; Susan Chalmers; Mairi E Sandison; Qin Liu; Ann Hedley; Tony McBryan; Hsin-Yao Tang; Nicole Gorman; Thomas Beer; David W Speicher; Peter D Adams; Xuefeng Liu; Richard Schlegel; John G McCarron; Michael J O Wakelam; Eyal Gottlieb; Andrew V Kossenkov; Zachary T Schug
Journal:  Br J Cancer       Date:  2020-01-16       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.